A Review of Statin Use and Prostate Cancer

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2014 Dec 1

PMID 25433554

Citations 5

Authors

Doreen Pon

Andrew Abe

Eric K Gupta

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the second most common cause of cancer and, when it metastasizes, has a high mortality rate. Statins may affect prostate cancer progression through cholesterol- and pleiotropic-mediated effects. The data on statin effects on prostate cancer has been mixed with benefit most likely occurring in reducing prostate cancer recurrence after radiation therapy and reduced mortality due to prostate cancer. More research is needed in this area to better characterize potential statin-mediated mechanisms that affect cancer. Also, future studies should report patients' anatomic/prognostic stage based on the updated staging system of the American Joint Committee on Cancer, which is a more effective predictor of recurrence and mortality than anatomic stage alone.

Citing Articles

Long-Term Treatment with Simvastatin Leads to Reduced Migration Capacity of Prostate Cancer Cells.

Kafka M, Gruber R, Neuwirt H, Ladurner M, Eder I Biomedicines. 2023; 11(1).

PMID: 36672537 PMC: 9855777. DOI: 10.3390/biomedicines11010029.

Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer.

Hayashi T, Fujita K, Matsushita M, Nonomura N Cancers (Basel). 2019; 11(8).

PMID: 31408948 PMC: 6721573. DOI: 10.3390/cancers11081153.

Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.

Han W, Gao S, Barrett D, Ahmed M, Han D, Macoska J Oncogene. 2017; 37(6):710-721.

PMID: 29059155 PMC: 5805650. DOI: 10.1038/onc.2017.385.

Effect of Statins on the Nanomechanical Properties of Supported Lipid Bilayers.

Redondo-Morata L, Sanford R, Andersen O, Scheuring S Biophys J. 2016; 111(2):363-372.

PMID: 27463138 PMC: 4968420. DOI: 10.1016/j.bpj.2016.06.016.

The association between regular use of aspirin and the prevalence of prostate cancer: Results from the National Health Interview Survey.

Huang W, Erickson S, Hansen R, Wu C Medicine (Baltimore). 2016; 95(25):e3909.

PMID: 27336878 PMC: 4998316. DOI: 10.1097/MD.0000000000003909.

References

Munoz-Pinedo C, El Mjiyad N, Ricci J . Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012; 3:e248. PMC: 3270265. DOI: 10.1038/cddis.2011.123. View

Konstantinopoulos P, Karamouzis M, Papavassiliou A . Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 2007; 6(7):541-55. DOI: 10.1038/nrd2221. View

Chao C, Williams S, Xu L, Chen J, Wallner L, Porter K . Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy. Cancer Lett. 2013; 335(1):214-8. DOI: 10.1016/j.canlet.2013.02.017. View

Lewis K, Holstein S, Hohl R . Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res. 2005; 29(5):527-33. DOI: 10.1016/j.leukres.2004.10.007. View

El-Saghire H, Vandevoorde C, Ost P, Monsieurs P, Michaux A, De Meerleer G . Intensity modulated radiotherapy induces pro-inflammatory and pro-survival responses in prostate cancer patients. Int J Oncol. 2014; 44(4):1073-83. PMC: 3977809. DOI: 10.3892/ijo.2014.2260. View

Allott E, Howard L, Cooperberg M, Kane C, Aronson W, Terris M . Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014; 114(5):661-6. PMC: 4153797. DOI: 10.1111/bju.12720. View

Rieken M, Kluth L, Xylinas E, Seitz C, Fajkovic H, Karakiewicz P . Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis. 2013; 16(4):367-71. DOI: 10.1038/pcan.2013.31. View

Thompson Jr I, Goodman P, Tangen C, Parnes H, Minasian L, Godley P . Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013; 369(7):603-10. PMC: 4141537. DOI: 10.1056/NEJMoa1215932. View

Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F . Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362(13):1192-202. DOI: 10.1056/NEJMoa0908127. View

10.

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366(11):981-90. PMC: 6027585. DOI: 10.1056/NEJMoa1113135. View

11.

Thibault A, Samid D, Tompkins A, Figg W, Cooper M, Hohl R . Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996; 2(3):483-91. View

12.

Geybels M, Wright J, Holt S, Kolb S, Feng Z, Stanford J . Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate. 2013; 73(11):1214-22. PMC: 3967507. DOI: 10.1002/pros.22671. View

13.

Colli J, Amling C . High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States. Urol Oncol. 2008; 27(2):170-3. DOI: 10.1016/j.urolonc.2007.11.029. View

14.

Yeganeh B, Wiechec E, Ande S, Sharma P, Moghadam A, Post M . Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther. 2014; 143(1):87-110. PMC: 4005604. DOI: 10.1016/j.pharmthera.2014.02.007. View

15.

Brown M, Hart C, Tawadros T, Ramani V, Sangar V, Lau M . The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer. 2012; 106(10):1689-96. PMC: 3349174. DOI: 10.1038/bjc.2012.138. View

16.

Zhuang L, Kim J, Adam R, Solomon K, Freeman M . Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005; 115(4):959-68. PMC: 1064980. DOI: 10.1172/JCI19935. View

17.

Chao C, Jacobsen S, Xu L, Wallner L, Porter K, Williams S . Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int. 2013; 111(6):954-62. DOI: 10.1111/j.1464-410X.2012.11639.x. View

18.

Caon J, Paquette M, Hamm J, Pickles T . Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?. Prostate Cancer. 2014; 2014:184297. PMC: 3960556. DOI: 10.1155/2014/184297. View

19.

Katz M, Carroll P, Cowan J, Chan J, DAmico A . Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int. 2010; 106(5):627-32. DOI: 10.1111/j.1464-410X.2010.09232.x. View

20.

Moyer V . Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157(2):120-34. DOI: 10.7326/0003-4819-157-2-201207170-00459. View